COVID-19 Immunity Offers Cross-Protection Against Related Bat Coronaviruses

The immune system's memory of COVID-19 appears to offer unexpected protection against a family of bat viruses that scientists have long worried could jump to humans. Researchers at The Pirbright Institute and King's College London discovered that people who recovered from COVID-19 or received vaccines against SARS-CoV-2 carry antibodies capable of neutralizing several closely related bat coronaviruses—viruses that, if they ever made the leap to human populations, could pose serious threats to public health.

The finding emerged from a systematic examination of how bat sarbecoviruses, the coronavirus subfamily that includes both SARS-CoV-1 and SARS-CoV-2, interact with ACE2, the cellular doorway that many coronaviruses use to enter host cells. The research team, funded by the UK's Biotechnology and Biological Sciences Research Council, the Wellcome Trust, and the Medical Research Council, tested 15 representative bat coronavirus spike proteins against ACE2 receptors from 34 different species—humans, livestock, rodents, and animals previously suspected as intermediate hosts. The work was published in two companion articles in PLOS Biology.

What emerged from this analysis was a striking pattern. The bat coronaviruses most capable of infecting a wide range of animal species—what researchers call "generalist" viruses—clustered within the same evolutionary group as SARS-CoV-2. These generalists included the BANAL viruses discovered in Laos, which have long concerned virologists as potential spillover candidates. In contrast, bat coronaviruses from other evolutionary branches, including a novel UK bat coronavirus called RhGB07, showed far more limited ability to use ACE2 receptors across species. They were specialists, adapted to narrow host ranges.

Dr. Nazia Thakur, the postdoctoral scientist who led the work, framed the implications carefully: the bat coronaviruses currently considered most likely to jump to humans are also the ones most likely to be recognized and neutralized by immunity already circulating in populations that have encountered COVID-19. While spillover cannot be prevented entirely, the widespread exposure to SARS-CoV-2 may have raised the barrier for related viruses to establish themselves in human populations. The team also tracked how SARS-CoV-2 itself evolved during the pandemic, finding that variants—particularly those in the Omicron lineage—acquired mutations that altered their ability to use ACE2 receptors across different animal species, demonstrating how viral evolution and host susceptibility remain in constant dialogue.

To test whether this theoretical protection held in practice, the researchers examined blood samples from people who had recovered from COVID-19. The antibodies in those samples successfully neutralized a range of closely related bat coronaviruses. Even more encouraging, the team detected lower levels of neutralization against more distant bat sarbecoviruses, suggesting that COVID-19 immunity offers some degree of broader protection across the entire subfamily. Katie Doores, Professor of Viral Immunology at King's College London, noted that the viruses showing the strongest antigenic similarity to SARS-CoV-2 were the ones most readily recognized and neutralized by COVID-19 antibodies, while the more distant specialists tended to evade this recognition.

In parallel experiments, researchers identified several monoclonal antibodies—laboratory-engineered immune proteins—capable of recognizing a remarkably diverse range of sarbecoviruses. A second companion article pinpointed exactly where these antibodies bind on the coronavirus spike protein, revealing conserved regions that remain unchanged across many different viruses. These findings offer a roadmap for developing next-generation vaccines and therapeutics that could protect against multiple sarbecoviruses at once. Dr. Dalan Bailey, head of Pirbright's Viral Glycoproteins group, highlighted the significance of detecting cross-neutralization even against more distant bat coronaviruses, suggesting that broadly protective vaccines or therapeutics targeting the entire sarbecovirus family may be within reach.

The research underscores a fundamental principle: understanding how viruses use receptors, which hosts they can infect, and how the immune system recognizes them must happen together, not in isolation. By identifying the characteristics that distinguish higher-risk viruses from those unlikely to spill over into humans, the work strengthens the foundation for global pandemic preparedness. The findings suggest that the next pandemic threat may not arrive as a complete surprise—that existing immunity from COVID-19 may already be standing guard against some of the most dangerous candidates waiting in bat populations.